Vimarsana
Biggest News Aggregation in the World

Page 48 - Clinical Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Sciences Today - Breaking & Trending Today

University of Bradford students pitch ideas to Bradford City | Bradford Telegraph and Argus - Vimarsana News

University of Bradford students pitch ideas to Bradford City | Bradford Telegraph and Argus

A LIFE-LONG Bradford City fan is among a group of local students who have had the opportunity to pitch their ideas to the club.

Thirty UCM Faculty Members Honored with Promotions/Tenure - Vimarsana News

Thirty UCM Faculty Members Honored with Promotions/Tenure

Following a review process coordinated by the Office of the Provost and Vice President for Academic Affairs, 30 University of Central Missouri faculty members were awarded promotions and/or tenure for the 2023-2024 academic year. The Board of Governors was presented a list of these individuals when it met March 23.

Source: ucmo.edu
Libtayo (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) - Vimarsana News

Libtayo (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)

29.03.2023 - Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice Approval marks second first-line ...

European Commission Approves Cemiplimab Plus Chemotherapy for First-line PD-L1+ NSCLC - Vimarsana News

European Commission Approves Cemiplimab Plus Chemotherapy for First-line PD-L1+ NSCLC

The European Commission has approved cemiplimab-rwlc plus platinum-based chemotherapy for the frontline treatment of patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without EGFR, ALK, or ROS1 alterations and who are not eligible for chemoradiation.

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration - Vimarsana News

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.